Pure Global: Hanoi's New AI Regulation - Navigating the Data Trap.

Failed to add items

Sorry, we are unable to add the item because your shopping basket is already at capacity.

Add to cart failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Follow podcast failed

Unfollow podcast failed

Pure Global: Hanoi's New AI Regulation - Navigating the Data Trap.

Listen for free

View show details

LIMITED TIME OFFER | Get 2 Months for ₹5/month

About this listen

This week, we dissect the sudden and impactful regulatory earthquake in Vietnam's MedTech sector. The Ministry of Health has released a new circular that reclassifies a huge swath of medical device software and AI tools into higher-risk categories, dramatically increasing the cost and time required for market approval. This isn't just about tougher standards. The new regulation also introduces a strict data localization mandate, forcing global companies to rethink their entire IT and data strategy for the Vietnamese market. We explore what this means on the ground and how manufacturers can navigate this challenging new landscape. A real-world example is a promising US-based scale-up with an AI-powered dermatology app that helps users screen for skin cancer. They were weeks away from launching in Vietnam under the old, simpler Class B pathway. Now, they are suddenly reclassified to Class C and face an unexpected, non-budgeted requirement to host all user data within Vietnam, forcing them to halt their launch and decide between a costly infrastructure investment or abandoning a key ASEAN market. Key Takeaways From This Episode: -What is Vietnam's new Circular 05/2026/TT-BYT and which device types are most affected? -How does reclassification from Class B to Class C impact your registration timeline and budget? -What are the specific technical and legal requirements of the new data localization rule? -Is this regulatory shift likely to spread to other ASEAN countries like Thailand or the Philippines? -How can you leverage your existing clinical data to meet the new, tougher evidence standards? -What are the hidden costs associated with setting up local data servers in Vietnam? -Should your company pause its entry into the Vietnamese market, or is there a strategic advantage to acting now? In a rapidly evolving market, staying ahead of regulatory changes is key to success. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using local expertise and advanced AI tools to streamline global market access. Whether you're navigating Vietnam's new circular, expanding into new markets, or managing post-market surveillance, we provide the strategic support you need. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn how we can help.

No reviews yet